Le-sha Zhang1, Jun Wang2, Jian-chun Chen3, Yi-min Tao1, Yu-hua Wang4, Xue-jun Xu1, Jie Chen1, Yun-gen Xu5, Tao Xi5, Xiao-wu Hu3, Yu-jun Wang1, Jing-gen Liu1. 1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica and Collaborative Innovation Center for Brain Science, Chinese Academy of Sciences, Shanghai 201203, China. 2. 1] State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica and Collaborative Innovation Center for Brain Science, Chinese Academy of Sciences, Shanghai 201203, China [2] Biotechnology Center, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China. 3. Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. 4. 1] Biotechnology Center, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China [2] School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China. 5. Biotechnology Center, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
Abstract
AIM: To characterize the pharmacological profiles of a novel κ-opioid receptor agonist MB-1C-OH. METHODS: [(3)H]diprenorphine binding and [(35)S]GTPγS binding assays were performed to determine the agonistic properties of MB-1C-OH. Hot plate, tail flick, acetic acid-induced writhing, and formalin tests were conducted in mice to evaluate the antinociceptive actions. Forced swimming and rotarod tests of mice were used to assess the sedation and depression actions. RESULTS: In [(3)H]diprenorphine binding assay, MB-1C-OH did not bind to μ- and δ-opioid receptors at the concentration of 100 μmol/L, but showed a high affinity for κ-opioid receptor (Ki=35 nmol/L). In [(35)S]GTPγS binding assay, the compound had an Emax of 98% and an EC50 of 16.7 nmol/L for κ-opioid receptor. Subcutaneous injection of MB-1C-OH had no effects in both hot plate and tail flick tests, but produced potent antinociception in the acetic acid-induced writhing test (ED50=0.39 mg/kg), which was antagonized by pretreatment with a selective κ-opioid receptor antagonist Nor-BNI. In the formalin test, subcutaneous injection of MB-1C-OH did not affect the flinching behavior in the first phase, but significantly inhibited that in the second phase (ED50=0.87 mg/kg). In addition, the sedation or depression actions of MB-1C-OH were about 3-fold weaker than those of the classical κ agonist (-)U50,488H. CONCLUSION: MB-1C-OH is a novel κ-opioid receptor agonist that produces potent antinociception causing less sedation and depression.
AIM: To characterize the pharmacological profiles of a novel κ-opioid receptor agonist MB-1C-OH. METHODS:[(3)H]diprenorphine binding and [(35)S]GTPγS binding assays were performed to determine the agonistic properties of MB-1C-OH. Hot plate, tail flick, acetic acid-induced writhing, and formalin tests were conducted in mice to evaluate the antinociceptive actions. Forced swimming and rotarod tests of mice were used to assess the sedation and depression actions. RESULTS: In [(3)H]diprenorphine binding assay, MB-1C-OH did not bind to μ- and δ-opioid receptors at the concentration of 100 μmol/L, but showed a high affinity for κ-opioid receptor (Ki=35 nmol/L). In [(35)S]GTPγS binding assay, the compound had an Emax of 98% and an EC50 of 16.7 nmol/L for κ-opioid receptor. Subcutaneous injection of MB-1C-OH had no effects in both hot plate and tail flick tests, but produced potent antinociception in the acetic acid-induced writhing test (ED50=0.39 mg/kg), which was antagonized by pretreatment with a selective κ-opioid receptor antagonist Nor-BNI. In the formalin test, subcutaneous injection of MB-1C-OH did not affect the flinching behavior in the first phase, but significantly inhibited that in the second phase (ED50=0.87 mg/kg). In addition, the sedation or depression actions of MB-1C-OH were about 3-fold weaker than those of the classical κ agonist (-)U50,488H. CONCLUSION: MB-1C-OH is a novel κ-opioid receptor agonist that produces potent antinociception causing less sedation and depression.
Authors: Flávio da S Bitencourt; Jozi G Figueiredo; Mário R L Mota; Carla C R Bezerra; Priscila P Silvestre; Marcus R Vale; Kyria S Nascimento; Alexandre H Sampaio; Celso S Nagano; Silvana Saker-Sampaio; Wladimir R L Farias; Benildo S Cavada; Ana M S Assreuy; Nylane M N de Alencar Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-02-13 Impact factor: 3.000
Authors: Lisa L Wilson; Amy R Alleyne; Shainnel O Eans; Thomas J Cirino; Heather M Stacy; Marco Mottinelli; Sebastiano Intagliata; Christopher R McCurdy; Jay P McLaughlin Journal: Molecules Date: 2022-06-04 Impact factor: 4.927
Authors: Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell Journal: J Pharmacol Exp Ther Date: 2020-09-10 Impact factor: 4.030
Authors: Wonder Kofi Mensah Abotsi; Stanley Benjamin Lamptey; Stephen Afrane; Eric Boakye-Gyasi; Ruth Uwa Umoh; Eric Woode Journal: Pharm Biol Date: 2017-12 Impact factor: 3.503
Authors: Liliana Mititelu Tartau; Maria Bogdan; Beatrice Rozalina Buca; Ana Maria Pauna; Cosmin Gabriel Tartau; Lorena Anda Dijmarescu; Eliza Gratiela Popa Journal: Medicina (Kaunas) Date: 2021-02-04 Impact factor: 2.430
Authors: Kelly F Paton; Katharina Robichon; Nikki Templeton; Lisa Denny; Afnan Al Abadey; Dan Luo; Thomas E Prisinzano; Anne C La Flamme; Bronwyn M Kivell Journal: Front Neurol Date: 2021-12-20 Impact factor: 4.003